AngioDynamics, Inc. (ANGO) – What Are Investment Firms Saying About This Stock?

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have received an average rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $19.00.

Several research firms have commented on ANGO. Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. HC Wainwright reduced their price target on AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price objective on shares of AngioDynamics in a report on Friday, October 9th.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This represents a 26.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 6.00% of the company’s stock.

Institutional Trading of AngioDynamics

Several institutional investors have recently modified their holdings of ANGO. BlackRock Inc. acquired a new stake in AngioDynamics in the second quarter valued at $49,480,000. Armistice Capital LLC raised its position in AngioDynamics by 3.9% during the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after purchasing an additional 64,000 shares during the last quarter. Weber Capital Management LLC ADV bought a new position in AngioDynamics during the 2nd quarter worth $17,649,392. Bastion Asset Management Inc. raised its position in AngioDynamics by 17.4% during the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock worth $14,107,000 after purchasing an additional 194,822 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in AngioDynamics by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock worth $10,786,000 after buying an additional 32,476 shares during the period. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Performance

Shares of ANGO opened at $11.05 on Thursday. AngioDynamics has a 52 week low of $9.39 and a 52 week high of $16.29. The stock has a market capitalization of $464.65 million, a price-to-earnings ratio of -14.17 and a beta of 0.30. The stock has a fifty day moving average of $15.08 and a 200-day moving average of $13.12.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. The business had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities analysts forecast that AngioDynamics will post -0.25 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.